J. Iglesias

M. Socinski, A. Makhson, J. Iglesias, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.

M. Socinski, I. Okamoto, V. Hirsh, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Flexible chemotherapy regimen with gemcitabine and vinorelbine for metastatic nonsmall cell lung carcinoma

Y. Cormier, V. Hirsh, J. Ayoub, 2001, Cancer.

Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103)

M. Stockler, P. Beale, D. Sommeijer, 2018, Cancer Chemotherapy and Pharmacology.

The influence of gemcitabine and cisplatin schedule on response and survival in advanced non-small cell lung cancer.

F. Shepherd, L. Crinò, A. Sandler, 2000, Lung cancer.

Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer.

F. Shepherd, U. Gatzemeier, H. Anderson, 1997, Seminars in oncology.

Survival results of a randomized, phase III trial of nab-paclitaxel and carboplatin compared with cremophor-based paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.

M. Socinski, I. Okamoto, V. Hirsh, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer.

S. Clarke, M. Millward, J. Latz, 2005, Lung cancer.

An open-label, multicenter, phase III trial of nab-paclitaxel (NP) versus dacarbazine (DTIC) in previously untreated patients (PTs) with metastatic malignant melanoma (MMM).

M. Millward, E. Hersh, J. Iglesias, 2010 .

Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival.

W. Gradishar, A. Makhson, J. Iglesias, 2012, Clinical breast cancer.

Abstract P1-12-07: A Retrospective Analysis ofnab-Paclitaxel as First-Line Therapy for Metastatic Breast Cancer Patients With Poor Prognostic Factors

W. Gradishar, J. O’Shaughnessy, J. Iglesias, 2012 .

Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study

N. Robert, J. O’Shaughnessy, J. Iglesias, 2010, Breast Cancer Research and Treatment.

Gemcitabine as First-Line Therapy in Patients with Metastatic Breast Cancer: A Phase II Trial

M. Blackstein, C. Vogel, A. Melemed, 2002, Oncology.

Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group.

K. Ding, A. Belch, M. Crump, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma

B. Costello, G. Sonpavde, H. Drabkin, 2015, Clinical Cancer Research.